Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia
These findings suggest that tocilizumab may be an effective and safe strategy for mitigating CAR-T-related CRS in R/R B-ALL patients, potentially improving patient outcomes and survival.
Authors
- Yuxin An (ORCID: https://orcid.org/0000-0003-4478-4479)
- Pengjiang Liu
- Xue Bai (ORCID: https://orcid.org/0000-0002-7283-3189)
- Hairong Lyu (ORCID: https://orcid.org/0000-0002-0367-8760)
- Haibo Zhu (ORCID: https://orcid.org/0000-0002-0515-9833)
- Cuicui Lyu (ORCID: https://orcid.org/0000-0002-0098-9408)
- Tianle Xie (ORCID: https://orcid.org/0009-0007-6298-1106)
- Xiaomei Zhang (ORCID: https://orcid.org/0000-0002-6530-3825)
- Xia Xiao (ORCID: https://orcid.org/0000-0002-9874-5240)
- Juanxia Meng
- Yu Zhang (ORCID: https://orcid.org/0000-0002-5592-111X)
- Huan Zhang (ORCID: https://orcid.org/0000-0003-2339-9942)
- Haotian Meng (ORCID: https://orcid.org/0000-0001-5869-8964)
- Yedi Pu
- Qianyi Zhou
Institutions
- Nankai University (CN)
- Tianjin First Center Hospital (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-03-14
- DOI
- https://doi.org/10.3389/fimmu.2025.1530623
- Citations
- 4
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 4.18